Study Evaluating Approach to Treatment of Haemophilia A and B in Spain

Completed

• Conditions: Hemophilia A; Hemophilia B

• Registration Number: NCT00581438
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain.

Detailed Description

Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.

Assess haemophilia A or B patient profile, study different kinds of hanitual clinical treatment of haemophilia A and B patients, and estimate the kind of treatment and dosage units used per year in patients under habitual clinical practice conditions.

Study Timeline

• Study Start: 2007-06
• Status Verified: 2007-12
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Study First Submitted: 2007-12-21
• Study First Submitted QC: 2007-12-26
• Last Update Submitted: 2007-12-26
• Study First Posted: 2007-12-27
• Last Update Posted: 2007-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• Haemophilia A or B patients of any age
• Written informed consent

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analyze the clinical and therapeutic approach to treament of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.	3 months

Secondary Outcome Measures

Name	Time	Method
Assess haemophilia A or B patient profile, study different kinds of habitual clinical treatment of haemophilia A and B patients, and estimate the dosage units used per year in patients under habitual clinical practice conditions.	3 months